The safety and efficacy of atezolizumab for recurrent primary liver cancer after liver transplantation
Abstract Background Immune checkpoint inhibitors (ICIs) have been proved to have certain therapeutic effects for primary liver cancer. However, the efficacy and safety of their applications in liver transplantation (LT) recipients with recurrent tumor remained unclear and even controversial. Methods...
Saved in:
| Main Authors: | Rong-Rong Yao, Quan-Bao Zhang, Meng-Xi Ge, Li Li, Jing Li, Xin-Li Zhou, Zheng-Xin Wang, Xiao-Hua Liang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-04-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02299-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Echography in liver transplantation: a literature review
by: L. V. Donova, et al.
Published: (2021-04-01) -
Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors
by: Mohammad Saeid Rezaee-Zavareh, et al.
Published: (2025-07-01) -
Tuning Autophagy for Improved Liver Transplant Outcomes: Insights from Experimental Models
by: Mina Kolahdouzmohammadi, et al.
Published: (2025-05-01) -
The incidence and risk factors of chronic rejection in acutely rejected pediatric liver transplantation
by: S. M. Dehghani, et al.
Published: (2022-01-01) -
Characteristics and Outcome of Partial Liver Transplant among Pediatrics in a Referral Transplant Center in Iran from 2010 to 2020
by: Pooya Vatankhah, et al.
Published: (2025-06-01)